# Who does Alnylam Pharmaceuticals pay? Who are its key suppliers?
Canonical: https://valuechain.wiki/alnylam-pharmaceuticals · Facet: suppliers · Updated: 2026-10-12T17:27:00.393+00:00 · Source: ValueChain.wiki (cited money-flow graph)

**Citable summary**: Alnylam Pharmaceuticals's confirmed suppliers/cost counterparties include Agilent Technologies, Inc. plus 1 undisclosed/aggregate relationship. Per the valuechain.wiki graph: 2 cost edges, backed by 2 dated sources, 1 of them primary filings (as of 2026-10-12).

### 애질런트 테크놀로지스 (high)  → /agilent-technologies.md
- note: Alnylam sole-sources API for AMVUTTRA, ONPATTRO and GIVLAARI from Agilent. Transaction value is not disclosed.
- [confirms] SEC EDGAR (EN, filing, published 2026-02-12) https://www.sec.gov/Archives/edgar/data/1178670/000162828026007497/alny-20251231.htm: "Agilent is currently the sole manufacturer of API for AMVUTTRA, ONPATTRO and GIVLAARI."
- [confirms] SK Securities (KO, research, published 2022-09-01) https://www.paxnet.co.kr/WWW/data/researchCenter/attach/20220901110145924.pdf: "SK Securities reported Alnylam’s agreement with Agilent to manufacture RNA therapeutic raw materials."

### 사노피 (high)
- note: Alnylam pays Sanofi royalties tied to global AMVUTTRA sales under TTR license agreements. The specific payment is not disclosed.
- [confirms] SEC EDGAR (EN, filing, published 2026-02-12) https://www.sec.gov/Archives/edgar/data/1178670/000162828026007497/alny-20251231.htm: "Alnylam pays Sanofi royalties on global AMVUTTRA sales, with the blended royalty rate increasing as sales grew."

Reverse side: https://valuechain.wiki/alnylam-pharmaceuticals/customers.md · Ripple: https://valuechain.wiki/alnylam-pharmaceuticals/ripple.md

---
Full node: https://valuechain.wiki/alnylam-pharmaceuticals.md · JSON: https://valuechain.wiki/alnylam-pharmaceuticals.json